Designing gene panels for tumor mutational burden estimation: the need to shift from ‘correlation’ to ‘accuracy’

Tumor mutational burden (TMB) assessment is at the forefront in precision medicine. The TMB could represent a biomarker for immune checkpoint inhibitors (ICIs) responses. Whole exome sequencing (WES) is the gold standard to derive the TMB; while targeted next-generation sequencing panels might be mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Hao-Xiang, Wang, Zi-Xian, Zhao, Qi, Wang, Feng, Xu, Rui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685228/
https://www.ncbi.nlm.nih.gov/pubmed/31387639
http://dx.doi.org/10.1186/s40425-019-0681-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685228/
https://www.ncbi.nlm.nih.gov/pubmed/31387639
http://dx.doi.org/10.1186/s40425-019-0681-2

Ejemplares similares